Eli Lilly stock up premarket as company’s Q1 revenue beats and it raises guidance

France Nouvelles Nouvelles

Eli Lilly stock up premarket as company’s Q1 revenue beats and it raises guidance
France Dernières Nouvelles,France Actualités
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

Eli Lilly & Co. shares rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance....

Eli Lilly & Co. shares LLY rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance. The company posted net income of $1.345 billion, or $1.49 a share, for the quarter, down from $1.903 billion, or $2.10 a share, in the year-earlier period. Adjusted per-share earnings came to $1.62, below the $1.73 FactSet consensus. Revenue fell 11% to $6.960 billion from $7.810 billion, but was ahead of the $6.

10 a share, in the year-earlier period. Adjusted per-share earnings came to $1.62, below the $1.73 FactSet consensus. Revenue fell 11% to $6.960 billion from $7.810 billion, but was ahead of the $6.864 billion FactSet consensus. The revenue decline was driven by lower volumes as demand for its COVID antibody treatment waned. Excluding that treatment, revenue rose 10%. R&D costs rose 23% to $1.99 billion, mostly due to higher development costs for late-stage assets.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

MarketWatch /  🏆 3. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Popular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company saysPopular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company saysA popular drug currently approved to treat Type 2 diabetes could soon also be approved for weight loss.
Lire la suite »

Eli Lilly’s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trialEli Lilly’s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trialEli Lilly & Co. said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage...
Lire la suite »

Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO saysBiogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO saysBiogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.
Lire la suite »

Rep. Eli Crane rips federal agency over tribal mine delaysRep. Eli Crane rips federal agency over tribal mine delaysRep. Eli Crane wrote to Interior Secretary Deb Haaland to encourage the feds to cut red tape holding up the tribe's mines.
Lire la suite »

Texans Pick 2nd Overall Thursday, Here's the History of that PickTexans Pick 2nd Overall Thursday, Here's the History of that PickThe Houston Texans have only been in existence for 21 total NFL seasons, so naturally, there are some things that the team has never done. Unfortunately, winning a Super Bowl and participating in a conference title game are two of this unfulfilled items. The bottom line is the team has...
Lire la suite »



Render Time: 2025-03-11 03:39:54